MannKind Stock Forecast for 2023 - 2025 - 2030
Updated on 03/29/2024
MannKind Stock Forecast and Price Target
MannKind's most recent price target of $6.75 for 2024 was provided by renowned analysts over the past few months, with an average prediction of $6.75. If this prediction is correct, MannKind's stock could rise by 46.42 percent from its current trading price. The potential increase for the stock is $6.75 per share, with a possible range of $5.00 to $10.00. Even if you are not interested in MNKD stock, you should still be aware of its competitors.
46.42% Upside
MannKind Fair Value Forecast for 2023 - 2025 - 2030
MannKind's Price has seen impressive growth In the last four years, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $5.00 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ABBV Stock Forecast | AbbVie | Outperform |
9
|
$179.63 | Buy/Sell | $178.42 | 0.21% |
AMGN Stock Forecast | Amgen | Outperform |
4
|
$275.36 | Buy/Sell | $303.65 | 14.40% |
GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$75.32 | Buy/Sell | $87.82 | 10.20% |
ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
BIIB Stock Forecast | Biogen | Outperform |
10
|
$230.07 | Buy/Sell | $299.62 | 29.09% |
MannKind Revenue Forecast for 2023 - 2025 - 2030
MannKind's Revenue has seen impressive growth In the last three years, rising from $65.14M to $198.96M – a growth of 205.43%. In the next year, analysts believe that Revenue will reach $268.71M – an increase of 35.06%. For the next seven years, the forecast is for Revenue to grow by 201.59%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$86.00 | Buy/Sell | $111.56 | 26.40% |
INCY Stock Forecast | Incyte | Outperform |
9
|
$60.79 | Buy/Sell | $77.05 | 26.99% |
ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$89.47 | Buy/Sell | $85.71 | 11.77% |
IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$15.10 | Buy/Sell | $20.42 | 68.87% |
ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$24.13 | Buy/Sell | $33.78 | 32.62% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$12.13 | Buy/Sell | $17.90 | 64.88% |
CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
CBAY Stock Forecast | CymaBay Therapeutics | Hold |
8
|
$32.44 | Buy/Sell | $27.73 | 0.18% |
MannKind EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, MannKind's EBITDA has seen an increase, rising from $-22.90M to $14.58M. This represents a growth of 163.67%. According to 0 prominent analysts, MannKind's EBITDA will fall by 203.06% in the next year, reaching $-15.03M. By 2030, professionals believe that MannKind's EBITDA will decrease by 256.72%, reaching $-22.85M – a concerning trend for the company.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$29.40 | Buy/Sell | $52.00 | 87.07% |
VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$63.44 | Buy/Sell | $34.00 | 73.39% |
DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
MannKind EBIT Forecast for 2023 - 2025 - 2030
MannKind's EBIT has seen growth In the last three years, going from $-24.79M to $10.59M – a gain of 142.72% In the next year, analysts believe that EBIT will reach $56.07M – an increase of 429.46%. For the next seven years, the forecast is forEBIT to grow by 2003.12%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$46.54 | Buy/Sell | $63.29 | 65.45% |
VCEL Stock Forecast | Vericel | Buy |
8
|
$44.59 | Buy/Sell | $42.58 | 18.86% |
ARDX Stock Forecast | Ardelyx | Buy |
11
|
$8.49 | Buy/Sell | $9.94 | 56.07% |
MannKind EPS Price Prediction Forecast for 2023 - 2025 - 2030
MannKind's EPS has seen impressive growth In the last four years, rising from $-0.20 to $0.00 – a growth of 100.00%. In the next year, analysts believe that EPS will reach $0.09 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$30.80 | Buy/Sell | $40.00 | 41.23% |
DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$12.97 | Buy/Sell | $25.00 | 88.90% |
XNCR Stock Forecast | Xencor | Outperform |
6
|
$23.13 | Buy/Sell | $37.91 | 47.00% |